The economic implications of cyclooxygenase-2-specific inhibitors (Q34137780)

31 July 2017

1 reference

title

The economic implications of cyclooxygenase-2-specific inhibitors (English)

1 reference

31 July 2017

Peloso PM

1

1 reference

31 July 2017

Scheiman JM

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

American Journal of Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

110 Suppl 3A

1 reference

31 July 2017

page(s)

50S-4S

1 reference

The economic cost of musculoskeletal disorders in Canada

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Economic and quality-of-life impact of NSAIDs in rheumatoid arthritis: A conceptual framework and selected literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Management of new symptoms of dyspepsia in the elderly in Quebec

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Prophylactic aspirin and risk of peptic ulcer bleeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

The iatrogenic cost of non-steroidal anti-inflammatory drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

inferred from DOI database lookup

7 January 2021

based on heuristic

The impact of disabling arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900619-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(01)00619-2

1 reference

release_pzjmsl43jbeqbm42stc54326hm

31 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pzjmsl43jbeqbm42stc54326hm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference